Fungal meningitis screening

Meningitis main page

Fungal meningitis Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fungal meningitis from other Diseases

Epidemiology and Demographics

Screening

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

ECG

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Fungal meningitis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fungal meningitis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fungal meningitis screening

CDC on Fungal meningitis screening

Fungal meningitis screening in the news

Blogs on Fungal meningitis screening

Directions to Hospitals Treating Fungal meningitis

Risk calculators and risk factors for Fungal meningitis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Prince Tano Djan, BSc, MBChB [2]

## Overview

[edit | edit source]

It is recommended that patients with CD4 counts ≤ 100 cells/μl, should have routine cryptococcal antigen screening. Patients with positive result are offered preemptive anti-fungal therapy.[1][2]

## Screening

[edit | edit source]

Screening is recommended in some types of fungal meningitis. Cryptococcal meningitis commonly affects patients with CD4 count are ≤ 100 cells/μl. It is responsible for major cause of mortality and morbidity in HIV individuals. It is recommended that patients with CD4 counts ≤ 100 cells/μl, should have routine cryptococcal antigen screening. Patients with positive result are offered preemptive anti-fungal therapy.[1][2]

## References

[edit | edit source]

1. ↑ 1.0 1.1 Cassim N, Schnippel K, Coetzee LM, Glencross DK (2017). "Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa". PLoS One. 12 (2): e0171675. doi:10.1371/journal.pone.0171675. PMID 28166254.CS1 maint: Multiple names: authors list (link)
2. ↑ 2.0 2.1 Greene G, Sriruttan C, Le T, Chiller T, Govender NP (2017). "Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease". Curr Opin HIV AIDS. 12 (2): 139–147. doi:10.1097/COH.0000000000000347. PMID 28134711.CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS